secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001213900-24-106646
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada halts REL-1017 Phase 3 trials after DMC review; begins strategic review
-------------------------------------------------------------------------------

- Discontinues Reliance II and Relight Phase 3 studies for major depressive disorder candidate REL-1017.
- Decision follows data monitoring committee evaluation of full Reliance II dataset.
- Will continue advancing Phase 1 study of REL-P11, a metabolic disease investigational agent.
- Commenced process to explore strategic alternatives including sale, merger, or asset acquisition.
- Engaging financial advisor; no timetable set for completion of strategic review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024106646/0001213900-24-106646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024106646/ea0224026-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-106646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer